NAMS
NewAmsterdam Pharma Company N.V. Ordinary SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.50B
P/E Ratio
—
EPS
$-1.72
Beta
0.13
52W High
$42.00
52W Low
$16.79
50-Day MA
$32.44
200-Day MA
$31.55
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V. is a pioneering biotechnology firm dedicated to developing innovative therapies for cardiometabolic diseases. Leveraging its proprietary technology platform, the company targets significant unmet medical needs and boasts a strong clinical development pipeline. With a seasoned leadership team and a commitment to advancing treatment paradigms, NewAmsterdam is well-positioned for growth and offers investors a compelling opportunity to engage in transformative therapeutic initiatives that aim to improve patient outcomes.
Fundamentals
| Revenue (TTM) | $22.50M |
| Gross Profit (TTM) | $22.50M |
| EBITDA | $-225.46M |
| Operating Margin | -206188.00% |
| Return on Equity | -28.30% |
| Return on Assets | -17.30% |
| Revenue/Share (TTM) | $0.19 |
| Book Value | $5.97 |
| Price-to-Book | 5.00 |
| Price-to-Sales (TTM) | 155.58 |
| EV/Revenue | 123.58 |
| EV/EBITDA | 27.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.80% |
| Shares Outstanding | $114.97M |
| Float | $71.47M |
| % Insiders | 0.97% |
| % Institutions | 105.39% |
Historical Volatility
HV 10-Day
51.21%
HV 20-Day
60.41%
HV 30-Day
57.49%
HV 60-Day
55.54%
HV Rank
64.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($49.61 target)
3
Strong Buy11
Buy1
HoldData last updated: 4/28/2026